Fig. 4
From: Non-coding single nucleotide variants affecting estrogen receptor binding and activity
The expression of GSTM1 in ER+ TCGA breast tumors (n = 385) is higher in rs36208869 carriers (n = 32) compared to WT carriers (n = 353). a The SNP array and RNA-seq data from TCGA were used for this comparison. Tumors containing the regSNV show significantly higher expression of GSTM1 compared to those with WT allele (adjusted p value = 1.25E-08). b The position of rs36208869 relative to the ERE located in the promoter of GSTM1. Binding score was calculated by Jaspar database tool (http://jaspar.genereg.net) c Disease-specific survival of ER+ patients from METABRIC (n = 1505) separated by upper quartile (q3) expression of GSTM1 (Illumina HT-12 v3 platform, probe: 1762255). d Recurrence-free survival of ER+ patients from the KM-plotter dataset (n = 1802) separated by upper quartile expression of GSTM1 (Affymetrix platform, probe: 204550_x_at)